# Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

> **NCT01593228** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 37 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Iniparib (SAR240550/BSI-201)
- **DRUG:** Carboplatin
- **DRUG:** Doxorubicin HCL liposome injection
- **DRUG:** Gemcitabine
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT01593228
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593228, "Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01593228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*